Indicated for patients with a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, the drug could be used in around 13% of the disease population. Sarepta’s share price almost ...

In this condition, patients' bodies don't make enough for the dystrophin protein necessary to keep muscles intact. Sarepta ...

In September, we shared 24-week dystrophin data from our FORWARD-53 trial, which included highly consistent mean muscle ...

Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is ...

WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...

Secondary outcomes included assessments of dystrophin expression and motor function. At 12 weeks, patients treated with Elevidys showed a mean micro-dystrophin expression of 34.29%, compared to 0% ...

Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...

Analyst Joseph Schwartz of Leerink Partners reiterated a Buy rating on PepGen Inc. (PEPG – Research Report), with a price target of ...

Duchenne, has been a transformative force in the fight against Duchenne muscular dystrophy (DMD). Following her son Hawken’s ...

Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress – – On track to submit gl ...

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...